SCHEMBL16610048

SCHEMBL16610048

CC(C)(C)[Si](C)(C)OCCc1ccc(OC(=O)c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.52
TDP1 Q9NUW8 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAOB P27338 1/20 0.49
KMT2A Q03164 7/20 0.46
ALDH1A1 P00352 2/20 0.46
PKM P14618 1/20 0.46
PPARG P37231 3/20 0.44
PARP10 Q53GL7 1/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
HSP90AA1 P07900 1/20 0.41
MEN1 O00255 2/20 0.41
THRB P10828 1/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
CTSL P07711 1/20 0.40
ELANE P08246 1/20 0.40
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610043 0.87 MAPT (0.55) MAPTTDP1L3MBTL1KMT2AALDH1A1
SCHEMBL16599389 0.82 TSHR (0.50) MAPTTDP1L3MBTL1KMT2AALDH1A1
SCHEMBL4741957 0.79 ALDH1A1 (0.44) MAPTKMT2AALDH1A1PPARGMEN1
SCHEMBL9185281 0.79 IDO1 (0.42) KMT2AALDH1A1RAB9AMEN1
SCHEMBL17951280 0.78 ESR1 (0.62) MAPTTDP1L3MBTL1MAOBKMT2A
SCHEMBL23066425 0.77 ESR1 (0.47) MAPTKMT2ARAB9ALMNAMEN1
SCHEMBL26039028 0.76 ESR1 (0.65) MAPTTDP1L3MBTL1MAOBKMT2A
SCHEMBL4254643 0.76 CYP4A11 (0.58) MAPTL3MBTL1KMT2AALDH1A1RAB9A
SCHEMBL3760690 0.76 KMT2A (0.60) MAPTTDP1L3MBTL1MAOBKMT2A
SCHEMBL17299381 0.76 LTA4H (0.50) MAOBKMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3049386-B9 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-11-18 EP disclosed
EP-3049386-B9 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-11-18 EP disclosed
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases UNIVERSITÄT ZU KOLN (DE) 2020-10-06 US disclosed
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases UNIVERSITÄT ZU KOLN (DE) 2020-10-06 US disclosed
EP-3049386-B1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-07-22 EP disclosed
EP-3049386-B1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIV KOELN (DE) 2020-07-22 EP disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2016-08-18 US disclosed
WO-2015044177-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES UNIVERSITÄT ZU KÖLN (DE) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237023-A1 COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES APC, BRCA1, VHL MAPT 1257/4885TDP1 3547/4885L3MBTL1 4300/4885
US-10793509-B2 Compounds useful in the treatment of neoplastic diseases APC, BRCA1, VHL MAPT 1257/4885TDP1 3547/4885L3MBTL1 4300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.